November 2022

Novel Targeted Immunotherapies in Multiple Myeloma, With a Focus on Bispecific Antibodies

By

November 10th 2022

Trending on OncLive

Dr Mesa on the FDA Approval of Ropeginterferon Alfa-2b for Essential Thrombocythemia

Zanidatamab Plus Chemotherapy Improves OS at Second Interim Analysis of HERIZON-GEA-01 in First-Line HER2+ GEA

Savolitinib Plus Osimertinib Improves First-Line PFS in MET-Overexpressing EGFR-Mutated NSCLC

TTFields Add a New Dimension to the Changing Pancreatic Cancer Treatment Paradigm

ASPEN-09-03 Trial Aims to Build the Case for Evorpacept in Post–T-DXd HER2+ Breast Cancer